Abstract:OBJECTIVE:3-Methylcrotonyl-coenzyme A carboxylase deficiency (MCCD) is an autosomal recessive inborn error of leucine catabolism. The cases suspected as MCCD detected by neonatal screening are not rare. The aim of the study was to investigate the clinical outcomes in cases suspected as MCCD by neonatal screening. The second aim was to investigate the mutation spectrum of MCC gene in Chinese population and hotspot mutation. METHOD:Forty-two cases (male 33, female 9) , who had higher blood 3-hydroxy-isovalerylcarnitine (C5-OH) levels(cut-off <0.6 µmol/L) detected by neonatal screening using MS/MS, were recruited to this study during Sept.2011 to Mar.2013. The C5-OH concentrations were [0.84 (0.61-20.15) µmol/L] in 42 cases at the screening recall. Five cases were firstly diagnosed as maternal MCCD, 6 cases as benign MCCD and 31 cases were suspected as MCCD. To follow up the height, weight, mental development, blood C5-OH concentrations and urinary 3-methylcrotonyl-glycine (3-MCG) and 3-hydroxy isovalerate (3-HIVA) in order to investigate the clinical outcome. The MCCC1 and MCCC2 gene mutation were analyzed for some cases. The novel gene variants were evaluated, and the influence of novel missense variants on the protein structure and function were predicted by PolyPhen-2, SIFT, UniProt and PDB software. RESULT:(1) Forty-two cases had no symptoms, their physical and mental development were normal in the last visit at the median ages of 29 months, the oldest age of follow up was nearly 9 years. (2) Gene mutation analysis was performed for 29 cases with informed consent signed by parents.Fourteen different mutations were identified in 19 cases. The mutations in MCCC1 gene accounted for 86%, the most common mutation was c.ins1680A, (accounted for 40%). Nine kinds of novel variant were detected including 211AG>CC/p.Q74P, c.295G>A/p.G99S, c.764A>C/p.H255P, c.964G>A/p. E322K, c.1331G>A/p.R444H, c.1124delT, c.39_58del20, c.1518delG, c.639+2T>A.Other 3 kinds of mutation in MCCC1 gene and 2 kinds of mutation in MCCC2 gene have been reported previously; the amino acid of mutant positions of five kinds of novel missense variant are almost highly conserved. These missense variants were predicted to cause change of human MCC protein side chain structure by changing hydrogen bonding, size of amino acid residue and electric charge, and predicted to damage the protein function possibly according to PolyPhen-2 and PDB analysis. So these novel variants may be disease-causing mutations. No mutation were detected in 10 cases. (3) Blood concentrations of C5-OH when screening, recall and end of follow-up in maternal MCCD was 3.50 (1.63-11.43), 1.84 (1.00-9.30), 0.27 (0.26-5.81) µmol/L. There was a significant downward trend.In contrast, benign MCCD group was 8.20 (3.60-9.60), 9.67 (3.88-20.15), 23.0 (5.87-49.10) µmol/L.It showed a rising trend. Children's urinary 3-MCG of benign MCCD group was found abnormally elevated in 4 cases (100%) when they were recalled. CONCLUSION:A certain number of cases with MCCD or suspected as MCCD in this study had no symptoms and normal physical and mental development after follow-up to oldest age of nearly 9 years. The mutation in MCCC1 gene is common, nine novel mutations were found, c.ins1680A may be a hotspot mutation in Chinese population. The urinary GC/MS analysis and blood MS/MS analysis for mother should be routinely performed for all cases with high blood C5-OH level detected by neonatal screening.

[Genetic Analysis and Treatment for an Infant with Cerebral Creatine Deficiency Syndrome Type 2].

Fourteen Cases of Cerebral Creatine Deficiency Syndrome in Children: a Cohort Study in China.

[Genetic Analysis of Newborns with Abnormal Metabolism of 3-Hydroxyisovalerylcarnitine].

[Clinical and Genetic Analysis of a Child with Cerebral Creatine Deficiency Syndrome Due to Variant of SLC6A8 Gene].

Long-term Follow-Up of Children with Carbamoyl Phosphate Synthase 1 Deficiency Detected in Newborn Screening.

[Clinical Features and SLC6A8 Gene Mutations of Cerebral Creatine Deficiency Syndrome I: an Analysis of Two Families].

First Reported Chinese Case of Guanidinoacetate Methyltransferase Deficiency in a 4-Year-old Child.

Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes.

Identification of novel variations in SLC6A8 and GAMT genes causing cerebral creatine deficiency syndrome

Response to therapy of creatine transporter deficiency caused by a hypomorphic variant in SLC6A8

Creatine Transporter Deficiency Presenting as Failure to Thrive: A Case Report of a Novel SLC6A8 Variant Causing a Treatable but Likely Underdiagnosed Genetic Disorder

[Clinical and genetic analysis of two pedigrees affected with Carnitine-acylcarnitine translocase deficiency due to variant of SLC25A20 gene]

Clinical and Genetic Analysis for Two Children with Congenital Disturbance of Glycosylation with PMM2 Gene Mutations

Clinical and genomic study of the infant with glycogen storage disease typeⅡ

Novel KRIT1/CCM1 and MGC4607/CCM2 Gene Variants in Chinese Families with Cerebral Cavernous Malformations

Clinical characteristics and genetic analysis of six children with carnitine palmitoyltransferase 2 deficiency.

[Follow Up and Gene Mutation Analysis in Cases Suspected As 3-Methylcrotonyl-coenzyme A Carboxylase Deficiency by Neonatal Screening].

[Analysis of Clinical Features of 6 Patients with Infantile Type Glycogen Storage Disease Type II].

Congenital disorder of glycosylation type 1a:a case report

A pilot study to estimate incidence of guanidinoacetate methyltransferase deficiency in newborns by direct sequencing of the GAMT gene

X-linked creatine transporter (SLC6A8) deficiency in females: Difficult to recognize, but a potentially treatable disease